Why the study?
Case reports and case series have described dramatic responses to intravenous immunoglobulin in people with presumed viral myocarditis, making its administration commonplace.
Does intravenous immunoglobulin (IVIG) improve outcomes in children and adults with presumed viral myocarditis?
Does intravenous immunoglobulin (IVIG) improve outcomes in children and adults with presumed viral myocarditis?
This review updates the evidence regarding the use of intravenous immunoglobulin (IVIG) for presumed viral myocarditis in children and adults.
Answers are grounded in this paper and cite their sources.
Insufficient evidence guides IVIG use in viral myocarditis; leaves open efficacy questions for definitive trials.
This is an update of a previous review. Case reports and case series have described dramatic responses to intravenous immunoglobulin (IVIG) in people with presumed viral myocarditis, and its administration has become commonplace.
No takes yet. Share an insight, caveat, or question.
Robinson et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: